Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

NRX Pharmaceuticals (NRXP) Debt to Equity (2024 - 2025)

NRX Pharmaceuticals (NRXP) has disclosed Debt to Equity for 2 consecutive years, with -$0.01 as the latest value for Q3 2025.

  • Quarterly Debt to Equity rose 94.16% to -$0.01 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$0.01 through Sep 2025, up 94.16% year-over-year, with the annual reading at -$0.01 for FY2024, N/A changed from the prior year.
  • Debt to Equity for Q3 2025 was -$0.01 at NRX Pharmaceuticals, up from -$0.46 in the prior quarter.
  • The five-year high for Debt to Equity was -$0.0 in Q1 2024, with the low at -$0.46 in Q2 2025.